NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free REGN Stock Alerts $968.00 +12.24 (+1.28%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$956.89▼$969.8850-Day Range$883.20▼$982.8252-Week Range$684.80▼$998.33Volume281,944 shsAverage Volume493,490 shsMarket Capitalization$106.25 billionP/E Ratio28.60Dividend YieldN/APrice Target$981.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside1.4% Upside$981.71 Price TargetShort InterestHealthy1.27% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.66Based on 28 Articles This WeekInsider TradingSelling Shares$7.78 M Sold Last QuarterProj. Earnings Growth4.04%From $38.86 to $40.43 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.00 out of 5 starsMedical Sector179th out of 915 stocksPharmaceutical Preparations Industry67th out of 426 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 15 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.27% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 2.11%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 2.6 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Regeneron Pharmaceuticals this week, compared to 14 articles on an average week.Search InterestOnly 12 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -15% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,779,766.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 4.04% in the coming year, from $38.86 to $40.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 28.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 28.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 170.75.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesMay 2, 2024 | insidertrades.comInsider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insider Sells 16,848 Shares of StockMay 8, 2024 | finance.yahoo.comLatest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 WeeksMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…May 8, 2024 | reuters.comRegeneron's experimental gene therapy improves hearing in one patientMay 8, 2024 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of "Moderate Buy" from AnalystsMay 7, 2024 | americanbankingnews.comRegeneron Pharmaceuticals' (REGN) Neutral Rating Reiterated at Cantor FitzgeraldMay 6, 2024 | globenewswire.comRegeneron Announces Investor Conference PresentationsMay 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regeneron on Strong Product Sales and Promising PipelineMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…May 6, 2024 | seekingalpha.comRegeneron: Dissecting The First Quarter Results And Regulatory SetbacksMay 4, 2024 | investorplace.com3 Biotech Stocks With the Potential to Make You an Overnight MillionaireMay 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regeneron on Strong Product Performance and Promising Pipeline DevelopmentsMay 4, 2024 | markets.businessinsider.comAssessing Regeneron Pharmaceuticals: Insights From 16 Financial AnalystsMay 4, 2024 | finance.yahoo.comRegeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...May 4, 2024 | finance.yahoo.comRegeneron Pharmaceuticals First Quarter 2024 Earnings: Misses ExpectationsMay 4, 2024 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call TranscriptMay 3, 2024 | investorplace.comShhh! 3 Secret Pharma Stocks Flying Below Wall Street's RadarMay 3, 2024 | americanbankingnews.comGeorge Yancopoulos Sells 16,848 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 3, 2024 | msn.comRegeneron’s stock climbs 4% as analyst look past earnings miss to focus on pipelineMay 2, 2024 | msn.comRegeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity InnovationMay 2, 2024 | msn.comRegeneron's blockbuster eye drug posts weaker sales due to inventory impactMay 2, 2024 | fool.comRegeneron's Q1 Results Came Up a Bit ShortMay 2, 2024 | msn.comRegeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlookMay 2, 2024 | finance.yahoo.comRegeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...May 2, 2024 | finance.yahoo.comRegeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration LoomsMay 2, 2024 | investorplace.comREGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 2, 2024 | seekingalpha.comRegeneron Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationSee More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/02/2024Today5/09/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$981.71 High Stock Price Target$1,189.00 Low Stock Price Target$720.00 Potential Upside/Downside+1.3%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)$33.85 Trailing P/E Ratio28.63 Forward P/E Ratio24.94 P/E Growth2.74Net Income$3.95 billion Net Margins29.45% Pretax Margin30.85% Return on Equity16.83% Return on Assets13.16% Debt Debt-to-Equity Ratio0.10 Current Ratio5.27 Quick Ratio4.51 Sales & Book Value Annual Sales$13.10 billion Price / Sales8.12 Cash Flow$43.82 per share Price / Cash Flow22.12 Book Value$236.63 per share Price / Book4.10Miscellaneous Outstanding Shares109,762,000Free Float100,070,000Market Cap$106.39 billion OptionableOptionable Beta0.17 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $8.18MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $7.76MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.68MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $2.01MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMs. Melissa LoznerSenior VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXGSKNYSE:GSKBristol-Myers SquibbNYSE:BMYSanofiNASDAQ:SNYZoetisNYSE:ZTSView All CompetitorsInsiders & InstitutionsBeacon Investment Advisory Services Inc.Bought 407 shares on 5/9/2024Ownership: 0.024%Ledyard National BankSold 454 shares on 5/9/2024Ownership: 0.006%WP Advisors LLCSold 40 shares on 5/9/2024Ownership: 0.003%Orion Portfolio Solutions LLCSold 36 shares on 5/9/2024Ownership: 0.002%Angeles Wealth Management LLCBought 11 shares on 5/9/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions REGN Stock Analysis - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price target for 2024? 20 equities research analysts have issued 1-year price objectives for Regeneron Pharmaceuticals' shares. Their REGN share price targets range from $720.00 to $1,189.00. On average, they expect the company's stock price to reach $981.71 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2024? Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of 2024. Since then, REGN shares have increased by 10.2% and is now trading at $968.00. View the best growth stocks for 2024 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings data on Friday, February, 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. The biopharmaceutical company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 16.83% and a net margin of 29.45%. The firm's revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company posted $10.96 EPS. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), VanEck Biotech ETF (BBH), Invesco Pharmaceuticals ETF (PJP), ProShares Ultra Nasdaq Biotechnology (BIB), Tema Oncology ETF (CANC), First Trust US Equity Opportunities ETF (FPX) and Invesco Biotechnology & Genome ETF (PBE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (0.81%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.37%), Global Assets Advisory LLC (0.32%), Swiss National Bank (0.29%), Sumitomo Mitsui Trust Holdings Inc. (0.29%) and TD Asset Management Inc (0.25%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More This page (NASDAQ:REGN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 Media348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.